Elderly Medical Patients Treated with Prophylactic Dosages of Enoxaparin
- 1 January 2007
- journal article
- clinical trial
- Published by Springer Nature in Drugs & Aging
- Vol. 24 (1) , 63-71
Abstract
Background The safety and optimal use of prophylactic treatment with low-molecular-weight heparins in elderly patients with impaired renal function remain undefined.Keywords
This publication has 28 references indexed in Scilit:
- Estimating renal function in older people: a comparison of three formulasAge and Ageing, 2006
- Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trialBMJ, 2006
- Safety Profile of Different Low-Molecular Weight Heparins Used at Therapeutic DoseDrug Safety, 2005
- Laboratory monitoring of low‐molecular‐weight heparin therapyJournal of Thrombosis and Haemostasis, 2004
- Assessment of the Risk and Prophylactic Treatment of Venous Thromboembolism in the ElderlyPathophysiology of Haemostasis and Thrombosis, 2003
- Low Molecular Weight Heparin for the Prevention of Deep Venous Thrombosis: A Suitable Monitoring in Elderly Patients?Pathophysiology of Haemostasis and Thrombosis, 2002
- How and When to Monitor a Patient Treated with Low Molecular Weight HeparinSeminars in Thrombosis and Hemostasis, 2001
- A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical PatientsNew England Journal of Medicine, 1999
- Occurrence of thrombosis and haemorrhage, relationship with anti‐Xa, anti‐IIa activities, and D‐dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgeryBritish Journal of Haematology, 1999
- Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosisThe Lancet, 1992